Name: A Multi-center, Randomized, Double-blind Clinical Trial to Evaluate the Safety and Tolerability of 24 Weeks Treatment With (50 mg qd) Versus Placebo in Patients With Type 2 Diabetes and Moderate or Severe Renal Insufficiency
Published: 2026-03-15T23:18:04.631527

Resumen

This clinical trial is designed to provide additional information on the safety and tolerability of vildagliptin (50 mg once daily (qd)) when used in patients with type 2 diabetes mellitus (T2DM) and moderate or severe renal insufficiency.

Elegibilidad

Edad mínima: 18 YearsEdad máxima: 85 YearsSexo: ALL

Criterios de inclusión

History T2DM
Moderate or Severe Renal Impairment

Criterios de exclusión

Glucose \> 270 mg/dL (\>15 mmol/L)

Intervenciones

drug

Vildagliptin

drug

Placebo

Ubicaciones

Buenos Aires, Argentina

Patrocinadores

PrincipalNovartis